Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR1 | P25024 | 11/20 | 0.73 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.63 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.63 |
| ▸ | CASP3 | P42574 | 1/20 | 0.57 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.57 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.57 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.57 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.57 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2403463 | 0.95 | CYP1A2 (0.69) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL7339631 | 0.90 | CYP1A2 (0.63) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL17951705 | 0.90 | CYP1A2 (0.67) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL6824168 | 0.88 | CXCR1 (0.58) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL17822356 | 0.87 | CYP1A2 (0.60) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL10929143 | 0.87 | CXCR1 (0.66) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL2353533 | 0.87 | RARB (0.64) | CXCR1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL7403884 | 0.87 | RARB (0.64) | CXCR1CYP1A2CYP19A1CYP2C9CYP2C19 | |
| SCHEMBL18314374 | 0.86 | CYP1A2 (0.70) | CXCR1NPC1RAB9ACYP1A2CYP19A1 | |
| SCHEMBL16557179 | 0.86 | CYP1A2 (0.59) | CXCR1NPC1RAB9ACYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11458189-B2 | Cytoprotective drugs | BALMES TRANSPLANTATION (FR) | 2022-10-04 | — | — | US | disclosed |
| US-20220040092-A1 | Ready to use injectable formulations of Micafungin Sodium | CITIBANK, N.A. | 2022-02-10 | — | — | US | disclosed |
| US-10954272-B2 | Method for acylating a cyclic peptide | Centrient Pharmaceuticals Netherlands B.V. | 2021-03-23 | — | — | US | disclosed |
| US-20170327540-A1 | METHOD FOR ACYLATING A CYCLIC PEPTIDE | Centrient Pharmaceuticals Netherlands B.V. (NL) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10954272-B2 | Method for acylating a cyclic peptide | VIP, NGLY1, PTMS | CXCR1 2085/4885NPC1 1254/4885RAB9A 4039/4885 |
| US-20170327540-A1 | METHOD FOR ACYLATING A CYCLIC PEPTIDE | VIP, NGLY1, PTMS | CXCR1 2085/4885NPC1 1254/4885RAB9A 4039/4885 |
| US-20220040092-A1 | Ready to use injectable formulations of Micafungin Sodium | ERG28, MEN1, MAN2B1 | CXCR1 1428/4885NPC1 131/4885RAB9A 777/4885 |
| US-11458189-B2 | Cytoprotective drugs | BAD, AIFM1, CASP3 | CXCR1 2608/4885NPC1 89/4885RAB9A 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.